Conference Call with Natco Pharma Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Natco Pharma announced Q2FY25 results Consolidated total revenue of Rs 1434.9 crore for the Q2FY25 as against Rs 1060.8 crore for the Q2FY24, reflecting a growth of 35.3%. Net profit for the period, on a consolidated basis, was Rs 676.5 crore as against Rs 369.0 crore Q2FY24, showing robust growth of about 83%. The Board of Directors has declared second interim dividend of Rs 1.50 per equity share, for FY25. Result PDF